Boxer Capital Management’s Contineum Therapeutics CTNM Stock Holding History
Bought
Maintained
Sold
Other funds holding CTNM
Boxer Capital Management's CTNM Position: Q3 2026 in Review
Boxer Capital Management held its Contineum Therapeutics (CTNM) position steady in Q3 2026 at 494,000 shares worth $6.63M. The position accounts for 0.58% of the portfolio, ranked #25.
Boxer Capital Management first reported a position in CTNM in Q4 2025 and has held it in 4 quarters since. The position peaked at $8.1M in Q2 2026. 118 funds tracked by Wall St. Rank hold CTNM as of Q3 2026.
- Boxer Capital Management held 494,000 shares of Contineum Therapeutics worth $6.63M as of Q3 2026.
- Boxer Capital Management left its Contineum Therapeutics share count unchanged in Q3 2026.
- Contineum Therapeutics made up 0.58% of Boxer Capital Management's portfolio in Q3 2026, its #25 holding.
- Boxer Capital Management first reported a position in Contineum Therapeutics in Q4 2025 and has held it in 4 quarters since.
- Boxer Capital Management's Contineum Therapeutics position peaked at $8.1M in Q2 2026.
- 118 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q3 2026.
Based on Boxer Capital Management's 13F filing for Q3 2026, filed 16 Nov 2026.